Delayed drug hypersensitivity: models of T-cell stimulation

Area of Science:

• Immunology
• Pharmacology
• Drug Hypersensitivity

Background:

• Drug-induced hypersensitivity reactions (DIHRs) are serious immune responses mediated by drug-specific T-cells.
• Traditionally explained by the hapten concept, where drugs covalently bind to proteins to form antigens.
• Recent observations of DIHRs with non-reactive drugs necessitate new explanations.

Purpose of the Study:

• To explore the mechanisms behind drug-induced hypersensitivity reactions.
• To investigate the role of direct drug-immune receptor interactions beyond the hapten concept.
• To elucidate the pharmacological interactions with immune receptors (p-i) concept in DIHRs.

Main Methods:

• Analysis of drug-specific T-cell clones (TCC) and their reactivity.
• Investigation of T-cell receptor (TCR) and major histocompatibility complex (MHC) interactions.
• Examination of drug binding to TCR versus MHC molecules, including HLA associations.

Main Results:

• The p-i concept proposes direct, reversible drug interactions with TCR and/or MHC molecules.
• Evidence suggests drugs may bind directly to TCRs or, in specific cases like abacavir with HLA-B*5701, to the MHC peptide-binding groove.
• Two pathways for p-i mediated reactions are proposed: direct TCR binding or MHC-bound drug recognition.

Conclusions:

• The p-i concept provides a framework for understanding DIHRs caused by both reactive and non-reactive drugs.
• Drug interactions with the immune system can occur directly with TCRs or indirectly via modified MHC molecules.
• Understanding these mechanisms is crucial for managing and preventing severe hypersensitivity reactions.